UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 497

Sortiert nach

Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach

The Lancet infectious diseases, 2016-04, Vol.16 (4), p.500-505

2016

Volltextzugriff (PDF)

Alternatives to antibiotics—a pipeline portfolio review

The Lancet infectious diseases, 2016-02, Vol.16 (2), p.239-251

2016

Volltextzugriff (PDF)

Designing development programs for non-traditional antibacterial agents

Nature communications, 2019-07, Vol.10 (1), p.3416-10, Article 3416

2019

Volltextzugriff (PDF)

Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America

Clinical infectious diseases, 2009-03, Vol.48 (5), p.503-535

2009

Volltextzugriff (PDF)

Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia

The Journal of infectious diseases, 2019-05, Vol.219 (10), p.1536-1544

2019

Volltextzugriff (PDF)

A comprehensive regulatory framework to address the unmet need for new antibacterial treatments

The Lancet infectious diseases, 2013-03, Vol.13 (3), p.269-275

2013

Volltextzugriff (PDF)

Has Antifungal Susceptibility Testing Come of Age?

Clinical infectious diseases, 2002-10, Vol.35 (8), p.982-989

2002

Volltextzugriff (PDF)

Guidelines for Treatment of Candidiasis

Clinical infectious diseases, 2004-01, Vol.38 (2), p.161-189

2004

Volltextzugriff (PDF)

Multicenter Clinical Evaluation of the (1→3) β-D-Glucan Assay as an Aid to Diagnosis of Fungal Infections in Humans

Clinical infectious diseases, 2005-09, Vol.41 (5), p.654-659

2005

Volltextzugriff (PDF)

A Prospective Observational Study of Candidemia: Epidemiology, Therapy, and Influences on Mortality in Hospitalized Adult and Pediatric Patients

Clinical infectious diseases, 2003-09, Vol.37 (5), p.634-643

2003

Volltextzugriff (PDF)

β-d-Glucan as a Diagnostic Adjunct for Invasive Fungal Infections: Validation, Cutoff Development, and Performance in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome

Clinical infectious diseases, 2004-07, Vol.39 (2), p.199-205

2004

Volltextzugriff (PDF)

Amphotericin B: Time for a New “Gold Standard”

Clinical infectious diseases, 2003-08, Vol.37 (3), p.415-425

2003

Volltextzugriff (PDF)

Antibiotic development - economic, regulatory and societal challenges

Nature reviews. Microbiology, 2020-05, Vol.18 (5), p.267-274

2020

Volltextzugriff (PDF)

Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United States

Antimicrobial Agents and Chemotherapy, 2003-10, Vol.47 (10), p.3149-3154

2003

Volltextzugriff (PDF)

Prospective Survey of (1[rightward arrow]3)-β-D-Glucan and Its Relationship to Invasive Candidiasis in the Surgical Intensive Care Unit Setting

Journal of Clinical Microbiology, 2011-01, Vol.49 (1), p.58-61

2011

Volltextzugriff (PDF)

The critical impact of time discounting on economic incentives to overcome the antibiotic market failure

Nature reviews. Drug discovery, 2012-02, Vol.11 (2), p.168-168

2012

Volltextzugriff (PDF)

ND4BB: addressing the antimicrobial resistance crisis

Nature reviews. Microbiology, 2014-04, Vol.12 (4), p.231-232

Rex, John H

2014

Volltextzugriff (PDF)

The value of single-pathogen antibacterial agents

Nature reviews. Drug discovery, 2013-12, Vol.12 (12), p.963-963

2013

Volltextzugriff (PDF)

Antibacterial R&D at a Crossroads: We’ve Pushed as Hard as We Can … Now We Need to Start Pulling

Clinical infectious diseases, 2021-12, Vol.73 (11), p.e4451-e4453

2021

Volltextzugriff (PDF)

Critical analysis of antibacterial agents in clinical development

Nature reviews. Microbiology, 2020-05, Vol.18 (5), p.286-298

2020

Volltextzugriff (PDF)

In Vitro Synergy of Caspofungin and Amphotericin B against Aspergillus and Fusarium spp

Antimicrobial Agents and Chemotherapy, 2002-01, Vol.46 (1), p.245-247

2002

Volltextzugriff (PDF)

Practice Guidelines for the Treatment of Candidiasis

Clinical infectious diseases, 2000-04, Vol.30 (4), p.662-678

2000

Volltextzugriff (PDF)

Effects of Serum on In Vitro Susceptibility Testing of Echinocandins

Antimicrobial Agents and Chemotherapy, 2007-11, Vol.51 (11), p.4214-4216

2007

Volltextzugriff (PDF)

Correlation between E-Test, Disk Diffusion, and Microdilution Methods for Antifungal Susceptibility Testing of Fluconazole and Voriconazole

Antimicrobial Agents and Chemotherapy, 2003-05, Vol.47 (5), p.1647-1651

2003

Volltextzugriff (PDF)

Fusariosis Associated with Pathogenic Fusarium Species Colonization of a Hospital Water System: A New Paradigm for the Epidemiology of Opportunistic Mold Infections

Clinical infectious diseases, 2001-12, Vol.33 (11), p.1871-1878

2001

Volltextzugriff (PDF)

1 – 25 von 497

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(460)
Mit Volltextzugriff
(402)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(310)
Life Sciences & Biomedicine
(284)
Humans
(234)
Biological And Medical Sciences
(143)
Medical Sciences
(126)
Microbiology
(104)
Male
(86)
Infectious Diseases
(82)
Female
(78)
Animals
(60)
Immunology
(55)
Middle Aged
(52)
Pharmacology & Pharmacy
(52)
Pharmacology. Drug Treatments
(47)
Antifungal Agents
(46)
Adult
(45)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(41)
Aged
(39)
Antifungal Agents - Therapeutic Use
(37)
Antifungal Agents - Pharmacology
(36)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach

Alternatives to antibiotics—a pipeline portfolio review

Designing development programs for non-traditional antibacterial agents

Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America

Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia

A comprehensive regulatory framework to address the unmet need for new antibacterial treatments

Has Antifungal Susceptibility Testing Come of Age?

Guidelines for Treatment of Candidiasis

Multicenter Clinical Evaluation of the (1→3) β-D-Glucan Assay as an Aid to Diagnosis of Fungal Infections in Humans

A Prospective Observational Study of Candidemia: Epidemiology, Therapy, and Influences on Mortality in Hospitalized Adult and Pediatric Patients

β-d-Glucan as a Diagnostic Adjunct for Invasive Fungal Infections: Validation, Cutoff Development, and Performance in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome

Amphotericin B: Time for a New “Gold Standard”

Antibiotic development - economic, regulatory and societal challenges

Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United States

Prospective Survey of (1[rightward arrow]3)-β-D-Glucan and Its Relationship to Invasive Candidiasis in the Surgical Intensive Care Unit Setting

The critical impact of time discounting on economic incentives to overcome the antibiotic market failure

ND4BB: addressing the antimicrobial resistance crisis

The value of single-pathogen antibacterial agents

Antibacterial R&D at a Crossroads: We’ve Pushed as Hard as We Can … Now We Need to Start Pulling

Critical analysis of antibacterial agents in clinical development

In Vitro Synergy of Caspofungin and Amphotericin B against Aspergillus and Fusarium spp

Practice Guidelines for the Treatment of Candidiasis

Effects of Serum on In Vitro Susceptibility Testing of Echinocandins

Correlation between E-Test, Disk Diffusion, and Microdilution Methods for Antifungal Susceptibility Testing of Fluconazole and Voriconazole

Fusariosis Associated with Pathogenic Fusarium Species Colonization of a Hospital Water System: A New Paradigm for the Epidemiology of Opportunistic Mold Infections

Suchergebnisse filtern